Skip to main content
Clinical Trials/PACTR202102566734864
PACTR202102566734864
Completed
Phase 1

Drug-drug interaction in the co-administration of the antiretroviral drugs and the antischistomicide praziquantel

AiBST0 sites32 target enrollmentMay 4, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
HIV/AIDS
Sponsor
AiBST
Enrollment
32
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 4, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
AiBST

Eligibility Criteria

Inclusion Criteria

  • Black Zimbabwean
  • Age between 18 and 40 years
  • BMI between 18 and 30
  • HIV, Hepatitis B and C negative
  • Able to give consent
  • Non\-smoking
  • Lab screening and ECG within the limits stipulated in the protocol
  • Healthy as determined by medical examination

Exclusion Criteria

  • HIV positive
  • any current or past history of psychiatric disorder
  • subjects receiving any prescription or over the counter product
  • use of any recreational drug
  • subjects who have eaten grapefruit or drunk grapefruit juice during the last 15 days before administration of study drug
  • subjects who had xanthine containing beverages (coffee, tea, chocolates, etc) 48 hours prior to study drug administration
  • history of hepatic, renal, GI, heart, lung, neurological, endocrine, chronic infections or disease
  • subjects suffering from any acute disease at screening or check in
  • Alanine S. Transaminase (AST)/ Alanine L. Transaminase (ALT) \>3 times upper limit of normal (ULN)
  • Bilirubin \>2\.5 times ILN

Outcomes

Primary Outcomes

Not specified

Similar Trials